Albuterol Base
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
ALBUTEROL BASE: Repurposing Evaluation — No Predictions Available
One-Sentence Summary
ALBUTEROL BASE is the free-base form of albuterol (salbutamol), a well-known short-acting beta-2 adrenergic agonist, but it is not currently registered under this name in the target regulatory jurisdiction. The TxGNN model returned no predicted new indications for this entry, and no supporting clinical trials or literature were retrieved from the evidence pipeline. This evaluation cannot advance beyond a preliminary assessment due to incomplete input data and the absence of predictions.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory registrations found) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | — (No predictions; insufficient input data) |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN predictions were generated for this entry, so a mechanistic rationale for a new indication cannot be provided at this time.
Based on general pharmacological knowledge, albuterol (salbutamol) is a selective short-acting beta-2 adrenergic receptor agonist, most widely recognised for relieving bronchospasm in asthma and COPD. The designation "BASE" refers to the free-base chemical form rather than the more commonly registered salt form (albuterol sulfate). This naming difference is the most likely explanation for zero regulatory matches — the substance is marketed globally under the INN salbutamol or as albuterol sulfate, not as "albuterol base."
The absence of predictions is likely a pipeline input problem rather than a genuine data gap for the molecule itself: the drug identifier did not resolve to a TxGNN knowledge graph node, preventing the model from generating any candidates. Once the identifier is corrected, a meaningful repurposing analysis should be feasible given albuterol's well-characterised pharmacology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
No regulatory registrations were found for ALBUTEROL BASE in the HSA database.
Naming note: Albuterol is registered globally under two alternative names — salbutamol (WHO International Nonproprietary Name, used in Singapore, UK, Australia) and albuterol sulfate (US convention). A repeat search using either of these names is strongly recommended before concluding that the molecule is absent from the Singapore market.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction pipeline returned no results for ALBUTEROL BASE, and all critical drug-level inputs — original indications, mechanism of action, and regulatory records — are absent; a repurposing evaluation cannot be meaningfully completed from the current evidence pack.
To proceed, the following is needed:
- Correct the drug identifier: Re-query using
salbutamoloralbuterol sulfateto match HSA regulatory records and the TxGNN knowledge graph node - Re-run the TxGNN pipeline with the corrected identifier to generate repurposing candidates
- Extract DrugBank data: The query log confirms a successful DrugBank hit (1 result) — populate MOA, original indications, and DrugBank ID from that result
- Retrieve safety data: Download and parse the HSA-approved package insert to populate key warnings and contraindications (currently blocking per DG001)
- Re-issue the evidence pack after the above corrections and regenerate this report
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.